




RealRate

PHARMACEUTICAL 2021

Sonoma Pharmaceuticals Inc
Rank 258 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 192% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 45% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	12,283
Cost of Goods Sold	9,806
Intangible Assets	0
Liabilities, Current	4,729
Liabilities, Non-Current	235
Other Assets	1,913
Other Compr. Net Income	0
Other Expenses	45
Other Liabilities	3,973
Other Net Income	4,127
Other Revenues	17,928
Property and Equipment	365
Research and Development	1,339
Selling, General and Administrative Expense	14,173

Output Variable	Value in 1000 USD
Assets	14,561
Liabilities	8,937
Expenses	25,363
Revenues	17,928
Stockholders Equity	5,624
Net Income	-3,308
Comprehensive Net Income	-3,308
BaseVar	35,458
ECR before Limited Liability	76%
Economic Capital Ratio	211%